Patents by Inventor Siri Tähtinen

Siri Tähtinen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Viral vector
    Patent number: 12337030
    Abstract: The invention concerns a novel viral vector with modified viral capsid or viral envelope; a pharmaceutical composition or immunogenic agent or vaccine comprising same; a target cell transformed or transfected with same; a combination therapeutic comprising same; use of same in treatment of cancer, and a method of treating cancer using same.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: June 24, 2025
    Assignee: Valo Therapeutics Oy
    Inventors: Vincenzo Cerullo, Cristian Capasso, Sara Feola, Siri Tahtinen
  • Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
    Publication number: 20230272108
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
    Type: Application
    Filed: September 30, 2022
    Publication date: August 31, 2023
    Inventors: Akseli Hemminki, Suvi Parviainen, Siri Tähtinen, Ilkka Liikanen, Mikko Siurala
  • Oncolytic adenoviruses coding for bi-specific antibodies
    Patent number: 11485791
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: November 1, 2022
    Assignee: TILT Biotherapeutics Oy
    Inventors: Akseli Hemminki, Suvi Parviainen, Siri Tähtinen, Ilkka Liikanen, Mikko Siurala
  • VIRAL VECTOR
    Publication number: 20220288184
    Abstract: The invention concerns a novel viral vector with modified viral capsid or viral envelope; a pharmaceutical composition or immunogenic agent or vaccine comprising same; a target cell transformed or transfected with same; a combination therapeutic comprising same; use of same in treatment of cancer, and a method of treating cancer using same.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 15, 2022
    Applicant: Valo Therapeutics Oy
    Inventors: Vincenzo Cerullo, Cristian Capasso, Sara Feola, Siri Tahtinen
  • Enhanced adoptive cell therapy
    Publication number: 20200399615
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Inventors: Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
  • Enhanced adoptive cell therapy
    Patent number: 10787645
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 29, 2020
    Assignee: TILT Biotherapeutics Oy
    Inventors: Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
  • Enhanced adoptive cell therapy
    Patent number: 10647963
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: May 12, 2020
    Assignee: TILT BIOTHERAPEUTICS OY
    Inventors: Akseli Hemminki, Markus Vaha-Koskela, Siri Tahtinen, Vincenzo Cerullo
  • Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
    Publication number: 20180072809
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 15, 2018
    Inventors: Akseli Hemminki, Suvi Parviainen, Siri Tähtinen, Ilkka Liikanen, Mikko Siurala
  • Enhanced adoptive cell therapy
    Publication number: 20170137786
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Application
    Filed: November 15, 2016
    Publication date: May 18, 2017
    Inventors: Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
  • Enhanced Adoptive Cell Therapy
    Publication number: 20150232880
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 20, 2015
    Inventors: Akseli Hemminki, Markus Vaha-Koskela, Siri Tahtinen, Vincenzo Cerullo